Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Genetic roadmap for metastatic breast cancer: CATCH trial aims to match patients to targeted therapies

NCT ID NCT05652569

Knowledge-focused Sponsor: German Cancer Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

The CATCH trial is a large observational study for people with metastatic breast cancer. It uses advanced genetic testing on tumor biopsies to find unique biomarkers and drug targets. The goal is to create a precision medicine platform that helps guide patients toward the most promising clinical trials and targeted treatments. This study does not test a new drug itself but aims to improve how treatments are chosen.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this platform could help match more metastatic breast cancer patients with targeted therapies and clinical trials tailored to their tumor's genetic profile.
What could go wrong
This is an observational diagnostic study, not a treatment trial. It may not directly improve outcomes, and genomic profiling may not always find actionable targets.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2017

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Advanced-stage / metastatic breast cancer patients (at the time point of progress)

Ages

14 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF) * Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines) * Patients, who agreed to and were able to sign the informed consent form. Exclusion Criteria: * Early breast cancer * Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient * Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Caritas Hospital St. Josef

    RECRUITING

    Regensburg, Germany

  • Charité

    RECRUITING

    Berlin, Germany

  • Medical Faculty and University Hospital Carl Gustav Carus

    RECRUITING

    Dresden, Germany

  • National Center for Tumor Diseases

    RECRUITING

    Heidelberg, Germany

  • Robert-Bosch-Krankenhaus Stuttgart

    RECRUITING

    Stuttgart, Germany

  • University Hospital Augsburg

    RECRUITING

    Augsburg, Germany

  • University Hospital Erlangen

    RECRUITING

    Erlangen, Germany

  • University Hospital Essen

    RECRUITING

    Essen, Germany

  • University Hospital Köln

    RECRUITING

    Cologne, Germany

  • University Hospital Tübingen

    RECRUITING

    Tübingen, Germany

  • University Hospital Ulm

    RECRUITING

    Ulm, Germany

  • University Hospital Würzburg

    RECRUITING

    Würzburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.